An Analysis of GST in Reference to Pharmaceutical Companies of Rajasthan: A Legal Study

The introduction of the Goods and Services Tax (GST) in India on 1 July 2017 brought a major transformation in the indirect taxation system by subsuming several central and state indirect taxes into a unified tax framework. The pharmaceutical sector is one of the strategically important sectors of the Indian economy because medicines, medical preparations and healthcare products have a direct relationship with public health. The application of GST to pharmaceutical companies has consequently generated important legal, fiscal and compliance issues. The present research paper examines the Goods and Services Tax regime with special reference to pharmaceutical companies operating in Rajasthan. The study analyses the constitutional and statutory framework of GST, including the Central Goods and Services Tax Act, 2017, the Integrated Goods and Services Tax Act, 2017, the Rajasthan Goods and Services Tax Act, 2017 and relevant rules, notifications and decisions affecting pharmaceutical businesses. Particular attention has been given to classification of pharmaceutical products under the Harmonised System of Nomenclature (HSN), tax-rate structures, input tax credit, inter-State and intra-State supplies, registration, invoicing, returns, reverse charge provisions, exports, compliance requirements and the legal challenges faced by pharmaceutical manufacturers, distributors and suppliers in Rajasthan. The study adopts a doctrinal and analytical methodology based on statutory provisions, government notifications, judicial decisions, official GST materials and secondary legal literature. The study finds that GST has substantially rationalised the indirect tax structure applicable to pharmaceutical businesses, but classification disputes, rate changes, input tax credit issues, compliance requirements and treatment of promotional and related business transactions continue to present legal and operational challenges. The research concludes that a clearer classification framework, stable tax policy, effective dispute resolution and technology-driven compliance mechanisms are important for ensuring greater certainty in taxation of the pharmaceutical sector.